MedPath

clinical trial of Pippali Rasayana and Nagaradi Kashaya Ghana Vati combination as an adjuvant treatment with ICMR guided medicines in Covid-19 positive mildly symptomatic cases

Phase 2
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2020/10/028230
Lead Sponsor
Government of India AYUSH EMR scheme
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1Patients with Covid -19 test positive (Confirmed using RT-PCR test)

2Covid-19 positive patients willing to participate in the study.

3Patients of either sex having age above 20 yrs. below 70 yrs.

4Covid-19 positive mildly symptomatic

Exclusion Criteria

1.Covid-19 positive patients having moderate to severe symptoms

2.Requiring immediate Intensive care.

3.Patients having complications of major illness such as Liver/Kidney failure

Encephalopathy, Epileptic attacks, Coagulopathies, Neuromuscular diseases, Cancer

4.Uncontrolled DM(HbA1C > 7.5) and its complications

5.Uncontrolled HTN and complications

6.Tuberculosis, Pleural Effusion, collapse of any lobe of Lung Ca Lung, COPD patients with dyspnea SPO2 <90, Respiratory rate > 20, requiring Nebulization frequently

7.Immunocompromised patients

8.Anemic patients having Hb <7 g/dl

9.BMI > 40

10.Pregnant and Lactating ladies

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Covid-19 positive mildly symptomatic patients will turn Covid negative after administration of combination of Pippali Rasayana +Nagaradi Kashaya Ghana Vati along with the ICMR guided treatment <br/ ><br>Recovery from the symptoms will be early and significant after administration of Pippali Rasayana +Nagaradi Kashaya Ghana Vati in mildly symptomatic Covid 19 positive patients <br/ ><br> <br/ ><br>Timepoint: Day 0 Day 14 <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
relief in associated symptoms if anyTimepoint: Day 0 Day 14
© Copyright 2025. All Rights Reserved by MedPath